CITIUS ONCOLOGY INC (CTOR) Stock Analyst Ratings
USA - NASDAQ:CTOR - US17331Y1091 - Common Stock
1.72 USD
0 (0%)
1.75 USD
+0.03 (+1.74%)
ChartMill assigns a Buy % Consensus number of 83% to CTOR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 255.81% above the current price.
CTOR was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CTOR.
In the last month the buy percentage rose by 40 points. So the trust of analysts is improving.
CTOR was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-23 | Maxim Group | Upgrade | Hold -> Buy |
| 2025-05-23 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-11-27 | Maxim Group | Initiate | Buy |
| 2024-08-13 | EF Hutton | Maintains | Buy -> Buy |
CITIUS ONCOLOGY INC / CTOR FAQ
What is the average price target for CITIUS ONCOLOGY INC (CTOR) stock?
7 analysts have analysed CTOR and the average price target is 6.12 USD. This implies a price increase of 255.81% is expected in the next year compared to the current price of 1.72.
Can you provide the consensus rating for CITIUS ONCOLOGY INC stock?
The consensus rating for CITIUS ONCOLOGY INC (CTOR) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.